The Therapeutic Goods Administration (TGA) has provisionally approved the Pfizer COVID-19 vaccine as a booster for young people aged 16 and 17 years old.
Dosing in this age group is the same as the adult population – a booster dose may be administered intramuscularly after the completion of a COVID-19 vaccine primary series (2 doses). This primary series can be of any of the COVID-19 vaccines approved for use in in this age group.
The Australian Technical Advisory Group on Immunisation will soon provide advice and further information on when this age group is eligible to receive booster doses.
For more information, see the TGA’s media release (28 Jan 2022).